When people hear the term “Chelation Therapy,” they often think of it as a last-resort detox method or something reserved for cases of heavy metal poisoning. However, this perspective is rapidly changing. In today’s world, where chronic exposure to toxins and environmental pollutants is common, chelation is being re-evaluated as a valuable tool in preventive, integrative, and functional health care.
Every day, our bodies face a constant battle against oxidative stress, chronic inflammation, and environmental toxins. As we age, cellular membranes weaken, vascular elasticity declines, and metabolic efficiency decreases—creating the perfect storm for chronic diseases and accelerated aging.
Many of these changes occur silently, long before any outward symptoms appear. That’s why more and more people focused on preventive health are turning to strategies that support cellular repair and vascular resilience.
One such approach gaining attention in Europe and Asia is PlaqX Therapy, a unique intravenous formulation designed to help restore inner vitality from the cellular level up.
In recent years, Ozempic® (Semaglutide) has attracted attention not only for managing type 2 diabetes but also for its noticeable effects on weight control. This isn’t merely a side effect—it’s a clinically observed benefit that’s changing the way we think about long-term metabolic support.
When we talk about cancer care, the focus often centers on active treatments like surgery, chemotherapy, or targeted therapies. However, supportive care strategies also play a critical role in helping the body recover, maintain stability, and rebuild its strength. Among these strategies, intravenous nutritional immunoglobulin therapy (IVIG) is emerging as a promising and gentle option for additional support.
In cancer care, most of the focus is placed on tumor markers, imaging results, or responses to treatment. Yet one often-overlooked blood marker—albumin—can quietly reflect a patient’s overall condition, prognosis, and even survival.
Though seemingly simple, this protein tells a deeper story about the body’s nutritional status, inflammation levels, and recovery capacity.
Have you been experiencing brain fog, memory lapses, or trouble focusing—without any clear reason?
While stress, poor sleep, and aging are often blamed, there might be an invisible culprit affecting your brain health: heavy metal accumulation in the body.
How BMS Supports Recovery Through Our Neurocognitive Health Program
When people hear the word cancer, they often think of tumors, genetic mutations, and clinical treatments like surgery, radiation, or chemotherapy. But in reality, cancer affects far more than just the physical body — it also places immense strain on the brain and emotional systems.
The wellness market is saturated with supplements—from vitamin C and D to herbal extracts and antioxidant blends.
Faced with overwhelming options, many people find themselves asking:
• “Do I really need to take all of these?”
• “Which one should I choose, and how much is enough?”
• “Are these supplements actually working for me?”
These questions point to the core issue:
Most people are making decisions about supplementation based on guesswork rather than science.
But in reality, nutritional support should be personalized, targeted, and data-driven.
This is where the RGCC Onconomics Plus test becomes a game-changer.
When we talk about early cancer detection, most people think of imaging tests or tumor markers.
These tools are valuable for identifying structural abnormalities or elevated markers — in other words, when a disease has already begun to manifest.
But what if you could go one step earlier?
Before anything is visible or measurable, is there a way to understand your underlying genetic risk?
Have you ever had a health checkup that came back “normal,” yet you still felt fatigued, foggy, or out of balance?
Or known someone who was diagnosed with cancer shortly after receiving clear test results?
These situations highlight a crucial gap:
Traditional checkups are important—but they focus on detecting existing issues, not predicting future risks.